LQDA Stock Forecast & Price Target

Liquidia is viewed positively because the global settlement with United Therapeutics removes the largest legal overhang, eliminates injunction risk, and preserves uninterrupted YUTREPIA commercialization in PAH, where the franchise now has clearer operating freedom and can compound physician adoption. The company’s fundamentals also look stronger after the preliminary 3Q26 YUTREPIA revenue of $222.7 million and cash balance of about $396 million, which suggest the current launch can fund the $175 million net payment and remaining installments while supporting continued execution. Beyond the core asset, management’s focus on PAH plus the optionality in L606 and other pipeline studies creates a credible path to long-term growth, even as PH-ILD sales step down and legal risk shifts mainly to future indications.

Liquidia is facing a difficult commercial path because Yutrepia must compete against entrenched pulmonary arterial hypertension leaders such as United Therapeutics and Actelion, with Tyvaso and Tyvaso DPI already serving as leading products in the market. The competitive burden is heightened by the prospect of additional entrants, which makes meaningful share capture and durable uptake less certain despite the company’s proprietary PRINT platform and focus on pulmonary hypertension. Financially, the company will likely incur significant and rising operating expenses to commercialize Yutrepia and L606 if approved, while requiring substantial capital and potentially resorting to future dilutive financings.